$34.20
+3.12 (+10.04%)
Open$31.89
Previous Close$31.08
Day High$34.61
Day Low$31.16
52W High$45.50
52W Low$4.97
Volume—
Avg Volume203.5K
Market Cap114.46M
P/E Ratio—
EPS$-5.52
SectorBiotechnology
Analyst Ratings
Strong Buy
5 analysts
Price Target
-53.9% upside
Current
$34.20
$34.20
Target
$15.75
$15.75
$10.91
$15.75 avg
$18.65
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 36.35M | 17.68M | 17.52M |
| Net Income | -35,208,259 | -69,679,191 | -1,532,650 |
| Profit Margin | -96.9% | -416.1% | -8.8% |
| EBITDA | -34,697,183 | -74,344,734 | -1,913,244 |
| Free Cash Flow | — | — | -1,533,941 |
| Rev Growth | +180.1% | -14.7% | +0.6% |
| Debt/Equity | — | 0.25 | 1.52 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 35.2 | 28.41B |